The expanded manufacturing facility will allow Albumedix to meet demand from a growing portfolio of clients
Albumedix has announced the completed expansion of its commercial-scale manufacturing facility, alongside with the establishment of a Technology Centre equipped with laboratories at its UK-based campus in Nottingham.
"Biopharmaceuticals has for a long time been a truly innovative corner of our industry; over the past 5-10 years we have experienced the incredible speed by which cellular and gene therapies have moved from jaw-dropping science to transformative therapies", Albumedix CEO Jonas Skjødt Møller comments and continues. "We are proud to play our part and remain committed to enable the global development of safe, stable and scalable therapies".
Following more than three years of design and construction, the company now officially manufactures out of its four-story manufacturing extension, significantly increasing its annual product capacity. "The expansion of the manufacturing capacity here in Nottingham is a huge accomplishment for our company and our Albumedix colleagues" said Albumedix´ Chief Manufacturing Officer Stuart Woodward.
The expanded manufacturing facility will allow Albumedix to meet demand from a growing portfolio of clients.
"It has been an exciting journey from design, through ground-breaking and finally construction of a four-story building towering over the campus", Woodward said. "Now fully operational, the number of batches coming through from our new and expanded facility are rapidly increasing and we are delighted to cement our commitment for secure supply of high-quality products to our valued customers and partners."
On the campus, a Technology Centre has now been established, with facilities classified at BSL2 and BSL2+. Phil Morton said: "This will allow us to enable more innovation and help drive a hand-held support for our customers in the advanced therapy field".
At the centre, the team will continue to support customers and investigate the benefits albumin can offer advanced therapy and biopharmaceutical developers. "As a science driven company, upgrading our research facilities builds upon our customer-centric philosophy and capabilities to support our customers and partners through our in-house expertise in albumin and its applications" Phil said.